Estimated impact of fezolinetant versus placebo on work productivity and indirect costs among women experiencing vasomotor symptoms associated with menopause

Key Points

• To evaluate the impact of fezolinetant on work productivity and indirect costs compared to placebo in women with vasomotor symptoms related to menopause.
• Randomized controlled trial design
• Comparison between fezolinetant and placebo
• Assessment of work productivity and cost implications
• 72-week follow-up period
• Fezolinetant significantly improved work productivity compared to placebo
• Estimated indirect costs were reduced with fezolinetant
• Improvements were sustained over 52 weeks
• Benefits recognized in women unsuitable for hormone therapy